Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Washington: - Virginia Mason Medical Center — Seattle, Washington
Phase 3 Recruiting Network
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spr…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04510597
Sites in Washington: - Overlake Medical Center — Bellevue, Washington
- Valley Medical Center — Renton, Washington
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital — Yakima, Washington
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Washington: - Valley Medical Center — Renton, Washington
- Legacy Cancer Institute Medical Oncology and Day Treatment — Vancouver, Washington
- Legacy Salmon Creek Hospital — Vancouver, Washington
Phase 3 Recruiting Industry
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Sponsor: Xynomic Pharmaceuticals, Inc.
NCT ID: NCT03592472
Sites in Washington: - Medical Oncology Associates, PS (dba Summit Cancer Centers) — Spokane, Washington
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- Overlake Medical Center — Bellevue, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Highline Medical Center-Main Campus — Burien, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
Phase 2 Recruiting Academic/Other
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with re…
Sponsor: NRG Oncology
NCT ID: NCT05327686
Sites in Washington: - Virginia Mason Medical Center — Seattle, Washington
Phase 2 Recruiting Network
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…
Sponsor: Children's Oncology Group
NCT ID: NCT04322318
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
- Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
- Madigan Army Medical Center — Tacoma, Washington
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07293351
Sites in Washington: - Local Institution - 0095 — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)…
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06682793
Sites in Washington: - Fred Hutch Cancer Center — Seattle, Washington
Phase 2 Recruiting Industry
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
NCT ID: NCT06281678
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT06047379
Sites in Washington: - Northwest Medical Specialties — Tacoma, Washington
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Washington: - Northwest Medical Specialties — Tacoma, Washington
- Northwest Cancer Specialists — Vancouver, Washington
Phase 1 Recruiting Industry
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalati…
Sponsor: HiberCell, Inc.
NCT ID: NCT06234605
Sites in Washington: - Swedish Medical Center — Seattle, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1 Recruiting Industry
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and …
Sponsor: Xencor, Inc.
NCT ID: NCT05433142
Sites in Washington: - Xencor Investigative Site — Seattle, Washington
Phase 1 Recruiting Industry
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17 vs. US-sourced Keytruda® in patients with resected non-smal…
Sponsor: Shanghai Henlius Biotech
NCT ID: NCT07160335
Sites in Washington: - American Oncology Network Vista Oncology Division — Olympia, Washington
- Northwest Medical Specialties PPLC (P1 Trials - Exigent Network ) — Tacoma, Washington
Phase 1 Recruiting Industry
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, an…
Sponsor: AstraZeneca
NCT ID: NCT06147037
Sites in Washington: - Research Site — Seattle, Washington
Phase 1 Recruiting Academic/Other
This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibili…
Sponsor: Seattle Children's Hospital
NCT ID: NCT07148050
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Highline Medical Center-Main Campus — Burien, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
Recruiting Network
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…
Sponsor: Children's Oncology Group
NCT ID: NCT02402244
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
- Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
- Madigan Army Medical Center — Tacoma, Washington
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Washington: - Massive Bio SYNERGY-AI site — Seattle, Washington
Recruiting Industry
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use …
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT04981119
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Recruiting Academic/Other
Partial nephrectomy (PN) is the standard treatment for localized renal masses and should be preferred in clinical T1 (\<7 cm tumor diameter) renal tumors over radical nephrectomy (RN) whenever technically feasible. Nonetheless, indications…
Sponsor: Azienda Ospedaliero-Universitaria Careggi
NCT ID: NCT05363657
Sites in Washington: - Swedish Hospital — Seattle, Washington
NA Recruiting Academic/Other
Prehabilitation refers to the process of improving a patient's functional capabilities prior to a surgical procedure with the goal of decreasing post-surgical inactivity and physical decline. This clinical trial evaluates the utility of a …
Sponsor: University of Washington
NCT ID: NCT06040762
Sites in Washington: - Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington